Zevra Therapeutics: Q4 Earnings Snapshot

Associated Press Finance03-11

CELEBRATION, Fla. (AP) — CELEBRATION, Fla. (AP) — Zevra Therapeutics, Inc. (ZVRA) on Tuesday reported a loss of $35.7 million in its fourth quarter.

The Celebration, Florida-based company said it had a loss of 67 cents per share.

The results fell short of Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 39 cents per share.

The specialty pharmaceutical company posted revenue of $12 million in the period, exceeding Street forecasts. Three analysts surveyed by Zacks expected $8.6 million.

For the year, the company reported a loss of $105.5 million, or $2.28 per share. Revenue was reported as $23.6 million.

_____

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on ZVRA at https://www.zacks.com/ap/ZVRA

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2518708373?lang=en_US&edition=full_marsco","thumbnail":"","is_english":true,"pubTime":"2025-03-12 05:22","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2518708373","market":"us","top_or_hot":-1,"title":"Zevra Therapeutics: Q4 Earnings Snapshot","media":"Associated Press Finance","content":"<html><body><p>CELEBRATION, Fla. (AP) — CELEBRATION, Fla. (AP) — <a href=\"https://laohu8.com/S/ZVRA\">Zevra Therapeutics</a>, Inc. (ZVRA) on Tuesday reported a loss of $35.7 million in its fourth quarter.</p>\n<p>The Celebration, Florida-based company said it had a loss of 67 cents per share.</p>\n<p>The results fell short of Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 39 cents per share.</p>\n<p>The specialty pharmaceutical company posted revenue of $12 million in the period, exceeding Street forecasts. Three analysts surveyed by Zacks expected $8.6 million.</p>\n<p>For the year, the company reported a loss of $105.5 million, or $2.28 per share. Revenue was reported as $23.6 million.</p>\n<p>_____</p>\n<p>This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on ZVRA at https://www.zacks.com/ap/ZVRA</p></body></html>","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Zevra Therapeutics: Q4 Earnings Snapshot</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nZevra Therapeutics: Q4 Earnings Snapshot\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-03-12 05:22 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/zevra-therapeutics-q4-earnings-snapshot-212214221.html><strong>Associated Press Finance</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>CELEBRATION, Fla. (AP) — CELEBRATION, Fla. (AP) — Zevra Therapeutics, Inc. (ZVRA) on Tuesday reported a loss of $35.7 million in its fourth quarter.\nThe Celebration, Florida-based company said it had ...</p>\n\n<a href=\"https://finance.yahoo.com/news/zevra-therapeutics-q4-earnings-snapshot-212214221.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://finance.yahoo.com/news/zevra-therapeutics-q4-earnings-snapshot-212214221.html","article_id":"2518708373","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2518708373","pubTimestamp":1741728134,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"CELEBRATION, Fla.  — CELEBRATION, Fla.  — Zevra Therapeutics, Inc.  on Tuesday reported a loss of $35.7 million in its fourth quarter.The Celebration, Florida-based company said it had a loss of 67 cents per share.The results fell short of Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 39 cents per share.The specialty pharmaceutical company posted revenue of $12 million in the period, exceeding Street forecasts. Three analysts surveyed by Zacks expected $8.6 million.For the year, the company reported a loss of $105.5 million, or $2.28 per share. Revenue was reported as $23.6 million.","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"Zevra Therapeutics：第四季度收益快照","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ZVRA":1},"content_text":"CELEBRATION, Fla. (AP) — CELEBRATION, Fla. (AP) — Zevra Therapeutics, Inc. (ZVRA) on Tuesday reported a loss of $35.7 million in its fourth quarter.\nThe Celebration, Florida-based company said it had a loss of 67 cents per share.\nThe results fell short of Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 39 cents per share.\nThe specialty pharmaceutical company posted revenue of $12 million in the period, exceeding Street forecasts. Three analysts surveyed by Zacks expected $8.6 million.\nFor the year, the company reported a loss of $105.5 million, or $2.28 per share. Revenue was reported as $23.6 million.\n_____\nThis story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on ZVRA at https://www.zacks.com/ap/ZVRA","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.32.1","shortVersion":"4.32.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2518708373"}